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S U M M A R Y
Objectives: To determine the prophylactic efﬁcacy of an Sm-p80-based vaccine formulation against
challenge infection with Schistosoma mansoni in mice using an approach comprising of initial priming
with DNA and boosting with recombinant protein in the presence of resiquimod (R848) as an adjuvant.
Methods: In the ﬁrst experiment (prime–boost approach), mice were primed with Sm-p80–pcDNA3
(week 0) and boosted at weeks 4 and 8with recombinant Sm-p80 formulated in resiquimod (R848). Each
mouse in the control group ﬁrst received only pcDNA3 and was boosted with R848. In the second set of
experiments (recombinant protein approach), micewere immunized (week 0) and boosted (weeks 4 and
8) with rSm-p80 formulated in R848. Animals of the control group in this series of experiments received
only R848 at 0, 4, and 8 weeks. All of the animals from both the ‘prime–boost’ and ‘recombinant protein’
groups were challengedwith cercariae of S. mansoni, 4 weeks after the last immunization. Themicewere
sacriﬁced 6 weeks post-challenge and the reductions in worm burden and egg production were
determined. Sm-p80-speciﬁc antibody titers were estimated in the mice sera by ELISA. Cytokine mRNA
and protein production by proliferating splenocytes in response to in vitro stimulation with Sm-p80,
were estimated via RT-PCR and ELISA, respectively.
Results: Vaccinationwith Sm-p80 (prime–boost approach) showed 49% reduction inwormburden;with
the recombinant protein approach the protection was found to be 50%. The protection levels were
correlated with antibody production. Upon antigenic stimulation with recombinant Sm-p80,
splenocytes secreted signiﬁcant levels of interferon (IFN)-g and interleukin (IL)-2, indicating that the
immune responses were Th1-biased and this was further supported in terms of distribution of antibody
isotypes and mRNA expression of cytokines.
Conclusions: In conclusion the present study clearly demonstrates that Sm-p80 consistently maintained
its protective nature, and resiquimod as an immunopotentiating agent slightly boosted the protective
effects of Sm-p80 in both ‘DNA prime–protein boost’ and ‘recombinant protein’ immunization
approaches in a murine model.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Schistosomiasis affects over 200million people, with 20million
seriously suffering from severe anemia, chronic diarrhea, internal
bleeding, and organ damage (e.g., intestine, liver and spleen)
caused by worms, and especially their eggs, and the immune
system reaction that the eggs provoke leading to the formation of
granulomas.1 Despite ongoing control efforts, schistosomiasis
remains a major source of morbidity in 76 countries, with 280
000 deaths per annum attributed to this disease in sub-Saharan
Africa alone.2,3* Corresponding author. Tel.: +1 806 743 2638; fax: +1 806 743 2334.
E-mail address: Afzal.Siddiqui@ttuhsc.edu (A.A. Siddiqui).
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doi:10.1016/j.ijid.2010.02.2266Currently schistosomiasis control is mainly based on the
treatment of infected individuals with praziquantel.4 The large
extension of endemic areas and constant reinfection of drug-
treated individuals, combined with the poor sanitary conditions in
tropical and subtropical countries, makes it necessary to look for
other control strategies in addition to drug treatment. To this effect
the advent of a prophylactic vaccine would be of great beneﬁt in
the sustainable control of schistosomiasis. A potent vaccine against
schistosomiasis is expected to enhance protective immune
responses in at-risk populations and thereby lead to reduced
worm burden and decreased egg production.5–7
Due to its signiﬁcant protective and antifecundity effects in
both rodent and nonhuman primate models, Sm-p80 is now
considered a leading putative vaccine candidate antigen for the
development of a schistosomiasis vaccine.4 In the present study, inses. Published by Elsevier Ltd. All rights reserved.
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immunoprotective efﬁcacy of the Sm-p80 vaccine candidate, we
used Sm-p80 in combination with resiquimod (R848), a low
molecular weight imidazoquinolinamine compound with immune
response modiﬁer properties, in ‘DNA prime–protein boost’ and
‘recombinant protein–resiquimod’ approaches.
2. Methods
2.1. Animals
Laboratory inbred female C57BL/6 mice were purchased from
Charles River Laboratories International Inc. (Wilmington, MA,
USA). At the outset of the immunization study the mice were 3–4
weeks old and weighed 10–12 g.
2.2. Parasites
Schistosoma mansoni (Puerto Rican strain)-infected Biompha-
laria glabrata snails were obtained from the National Institute of
Allergy and Infectious Diseases Schistosomiasis Resource Center
(Biomedical Research Center, Rockville, MD, USA). The cercariae
were collected from these snails. The viability of the larvae was
determined under an optical microscope.
2.3. Vaccination schedules and challenge infection
For the entire immunization study, a total of 60 mice were
divided into the four major groups, each consisting of 15 animals.
Each major group of mice was subdivided into two subgroups
comprising seven and eight mice and each of the subgroups
processed as independent experiments to obtain two repeats.
Animals in experimental group I (prime–boost experimental group)
were inoculated intramuscularlywith100mg Sm-p80–pcDNA3and
boosted with 25mg recombinant Sm-p80 protein containing 10mg
resiquimod (R848) at week 4 andweek 8. The animals in the control
group for this experiment (control group I or prime–boost control
group) were immunized with 100mg naked pcDNA3 and boosted
with 10mg R848 at the same time intervals as described above.
Animals in experimental group II (recombinant protein experimen-
tal group) were immunizedwith 25mg rSm-p80 protein containing
10mgR848andboostedatweek4andweek8with the samevaccine
formulation. The animals for the control group (control group II or
recombinant protein control group) of this experiment received
10mg R848 at 0, 4, and 8weeks. Blood samples were collected prior
to the immunization and biweekly thereafter. Four weeks after the
secondboost, all of the animalswere challengedwith150 S.mansoni
cercariae via tail exposure method.
2.4. Necropsy and estimation of worm and egg burdens in
the animal tissue
Forty-six days after the challenge infection, all of the animals
were sacriﬁced. The wormswere recovered from the portal system
by perfusion and also manually removed from the mesenteric
veins. Thewormburden reduction ratewas calculated as described
previously.8 The liver and intestine from individual animals in all
the fourmajor groups (eight subgroups)were removed at necropsy
and digested overnight at 37 8C in 4% KOH; the numbers of eggs
were counted by two independent individuals before calculating
the egg burdens.
2.5. Estimation of antibody responses
An enzyme-linked immunosorbent assay (ELISA) was used to
determine the levels of IgG (and its isotypes), IgA, and IgMantibodies. Details of the ELISA protocols have been described
previously.8–10 The antibody responses in the pooled sera were
determined in all four groups (eight subgroups) of animals
involved in the present study. The results are expressed as mean
end-point titers  standard error (SE).
2.6. Estimation of key Th1- and Th2-type cytokines by ELISA
For the estimation of various cytokines in the culture super-
natants, the single cell suspensions of pooled splenocytes from
each group of animals were prepared and cultured/stimulated in
vitro with Sm-p80 for 48 h, as described previously.11 The
concentrations of interleukin (IL)-2, IL-4, IL-10, and interferon
(IFN)-g were measured by ELISA using the eBioscience ELISA
Ready-Set-Go Kit (eBioscience, San Diego, CA, USA) according to
the manufacturer’s instructions.
2.7. Estimation of expression of cytokine mRNA by RT-PCR in
vaccinated and control groups
Splenocytes of C57BL/6 mice were cultured in the presence or
absence of rSm-p80 protein for 48 h. The details of culture media
and the cell culture method have been described previously.11
Total RNA was extracted by TRIzol reagent as per the manufac-
turer’s instructions (Invitrogen Corp., Carlsbad, CA, USA). Details of
the reverse transcription reactions for the ﬁrst strand cDNA
synthesis are described elsewhere.12 Expression levels of the
following cytokines: IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-
8 (= MIP-2), IL-9, IL-10, IL-11, IL-12a, IL-12b, IL-13, IL-14, IL-15, IL-
16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, tumor necrosis
factor (TNF)-a, IFN-g, transforming growth factor (TGF)-b1, and
TGF-b2 and the expression level of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) were determined by RT-PCR. The
protocol details have been described previously.13–18
2.8. Statistical analysis
The computer program SPSS (SPSS Inc., Chicago, IL, USA) was
used for the statistical analyses. One-way analysis of variance
(ANOVA) was used to calculate the signiﬁcance between the two
groups. The paired t-test was employed to determine in-group
signiﬁcance. In order to avoid reaching a false conclusion,
Bonferroni adjustments were included and the results were
considered statistically signiﬁcant if the p-value was <0.05.
3. Results
3.1. Appraisal of the protective efﬁcacy of vaccination
As shown in Table 1, both ‘DNA prime–protein boost’ and
‘recombinant protein’ immunization approaches in combination
with the immunomodulatory agent resiquimod (R848) signiﬁ-
cantly reduced the worm burden in the vaccinated animals as
compared with the respective control groups, which received
either plasmid DNA with R848 or R848 alone. Resiquimod boosted
the protective nature of candidate vaccine Sm-p80 to 49% in
‘prime–boost’ experiments and to 50% in ‘recombinant protein’
experiments.
3.2. Reduction in eggs entrapped in the tissues of the vaccinated
animals
Since the vaccine effect on egg output is one of the parameters
for an effective anti-morbidity vaccine, we measured the response
of the two vaccine regimens on egg production by determining the
entrapped eggs in liver and intestine of the vaccinated animals. In
Table 1
Anti-worm effects in C57BL/6 mice following immunization either with prime–boost regimen ((Sm-p80–pcDNA3)–(rSm-p80–R848)) or only with the recombinant protein
(rSm-p80–R848)
Immunization group Mean SE worm burden/mouse (n) Total for two
experiments (n)
% reduction in
worm burden
Experiment 1 Experiment 2
Control prime–boost (pcDNA3–R848) 28.424.95 (7) 31.285.34 (7) 29.855.15 (14) -
Experimental prime–boost ((Sm-p80–pcDNA3)–(rSm-p80–R848)) 13.163.04 (6) 17.004.15 (7) 15.083.59 (13) 49.49
Control protein vaccine (R848) 25.284.29 (7) 28.503.45 (8) 26.893.87 (15) -
Experimental protein vaccine (rSm-p80–R848) 15.332.88 (6) 11.282.04 (7) 13.302.46 (13) 50.53
Table 2
Anti-egg effects in C57BL/6 mice following immunization either with prime–boost regimen ((Sm-p80–pcDNA3)–(rSm-p80–R848)) or only with the recombinant protein
(rSm-p80–R848)
Immunization group Mean SE egg burden/mouse (n) Total for two
experiments (n)
% reduction in
egg burden
Experiment 1 Experiment 2
Control prime–boost (pcDNA3–R848) 256.78268.41 (7) 839.81442.99(7) 683.30155.70 (14) -
Experimental prime–boost ((Sm-p80–pcDNA3)–(rSm-p80–R848)) 229.21229.21 (6) 719.49566.54(7) 474.30397.87 (13) 30.57
Control protein vaccine (R848) 536.86291.89 (7) 645.13270.73 (8) 590.99281.31 (15) -
Experimental protein vaccine (rSm-p80–R848) 452.72270.66 (6) 538.65316.95(7) 495.68293.80 (13) 16.12
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approximate 30% reduction in egg count was recorded in the
tissues of vaccinated animals. In animals vaccinated via ‘recombi-
nant protein’ approach, the reduction in egg production was found
to be 16% (Table 2).
3.3. Titers of anti-Sm-p80 antibody responses
Sera from the control and vaccinated C57BL/6 mice were
examined in order to determine the titers of total IgG, IgG1, IgG2a,
IgG2b, IgG3, IgM, and IgA using ELISA. The end-point titers for all
these antibodies are shown in Tables 3–9. Brieﬂy, as shown in
Table 3, in the case of the DNA prime–protein–R848 boost group of
animals, the total IgG titer started rising 6 weeks after initial
immunization, and at 12weeks post-vaccination the antibody titer
in this groupwas 1:204800. In the case of protein–R848 vaccinated
animals, the titer of IgG rose quickly just 2 weeks after initialTable 3
End-point titers of anti-Sm-p80 total IgG in the sera of C57BL/6 mice following immun
only with the recombinant protein (rSm-p80–R848)
Week Control prime–boost
(pcDNA–R848)
Experimental prime–boost
((Sm-p80–pcDNA3)–(rSm-p8
0 10013.18 1004.35
2 10010.49 1005.04
4 10012.06 10014.18
6 10014.00 12 8005443.68
8 1002.56 204 8002872.60
10 100 0.93 204 8001230.58
12 1001.91 204 8002844.44
Table 4
End-point titers of anti-Sm-p80 IgG1 in the sera of C57BL/6 mice following immunizatio
with the recombinant protein (rSm-p80–R848)
Week Control prime–boost
(pcDNA–R848)
Experimental prime–boost
((Sm-p80–pcDNA3)–(rSm-p8
0 1004.05 1001.43
2 1004.00 1002.70
4 100 0.00 1007.69
6 1004.21 4006.30
8 1001.64 8000.00
10 1003.28 640093.66
12 1002.94 640043.54immunization and remained high at 12 weeks post-vaccination
(end-point titer = 1:204 800). In contrast, sera from the control
animals immunized either with pcDNA or immunomodulatory
agent R848 did not react with rSm-p80 (Table 3).
IgG1 antibody levels were similar in both the vaccine regimens,
with 1:6400 titers at 12 weeks post-immunization (Table 4). Both
IgG2a and IgG2b started rising early in the case of the recombinant
Sm-p80 protein–R848 vaccinated group at 2 weeks post-immuni-
zation, but the end-point titers for both the ‘DNA prime–protein
boost’ and ‘recombinant protein’ vaccinated animals were the
same at the 1:25 600 level (Tables 5 and 6).
A very high titer of IgG3 antibody was observed in both vaccine
regimen groups of mice, as can be seen in Table 7. The IgG3
antibody titer for both vaccination formulationswas 1:51 200 at 12
weeks post-immunization, although the initial rise in the IgG3
level was slow for the ‘DNA prime–protein boost’ vaccine
group (Table 7). As expected, the IgM titer initially rose for bothization either with prime–boost regimen ((Sm-p80–pcDNA3)–(rSm-p80–R848)) or
0–R848))
Control protein
vaccine (R848)
Experimental protein
vaccine (rSm-p80–R848)
1003.23 10012.69
1007.32 80044.29
1009.45 64001459.65
1009.76 6400829.63
1004.12 204 8005639.20
1002.56 204 8002377.43
10014.53 204 8004850.26
n either with prime–boost regimen ((Sm-p80–pcDNA3)–(rSm-p80–R848)) or only
0–R848))
Control protein
vaccine (R848)
Experimental protein
vaccine (rSm-p80–R848)
1002.82 1009.33
1004.11 1002.63
100 0.00 1001.54
1002.63 1600112.56
1001.64 160073.85
1004.76 6400124.68
100 0.00 6400562.64
Table 5
End-point titers of anti-Sm-p80 IgG2a in the sera of C57BL/6 mice following immunization either with prime–boost regimen ((Sm-p80–pcDNA3)–(rSm-p80–R848)) or only
with the recombinant protein (rSm-p80–R848)
Week Control prime–boost
(pcDNA–R848)
Experimental prime–boost
((Sm-p80–pcDNA3)–(rSm-p80–R848))
Control protein vaccine
(R848)
Experimental protein vaccine
(rSm-p80–R848)
0 10010.71 1001.89 1002.86 1006.60
2 1003.81 1001.04 1001.00 2004.76
4 10013.64 100 0.00 1002.97 80011.85
6 1006.56 160021.77 1005.65 6400693.98
8 10010.68 640035.96 1001.02 12 800874.53
10 1005.00 25 6003020.22 1008.77 25 6001855.07
12 1007.22 25 6001404.88 10023.33 25 6001338.56
Table 6
End-point titers of anti-Sm-p80 IgG2b in the sera of C57BL/6 mice following immunization either with prime–boost regimen ((Sm-p80–pcDNA3)–(rSm-p80–R848)) or only
with the recombinant protein (rSm-p80–R848)
Week Control prime–boost
(pcDNA–R848)
Experimental prime–boost
((Sm-p80–pcDNA3)–(rSm-p80–R848))
Control protein
vaccine (R848)
Experimental protein
vaccine (rSm-p80–R848)
0 1005.09 1007.18 1000.43 1009.50
2 1000.92 40013.12 1004.55 80048.39
4 1004.37 80026.23 1000.44 3200359.69
6 1003.83 6400176.38 1006.07 12 800294.25
8 1007.80 25 6001808.18 1005.69 25 6001786.05
10 1005.29 25 6001983.76 1005.88 25 600973.38
12 1007.59 25 6002822.81 1004.67 25 6001835.13
Table 7
End-point titers of anti-Sm-p80 IgG3 in the sera of C57BL/6 mice following immunization either with prime–boost regimen ((Sm-p80–pcDNA3)–(rSm-p80–R848)) or only
with the recombinant protein (rSm-p80–R848)
Week Control prime–boost
(pcDNA–R848)
Experimental prime–boost
((Sm-p80–pcDNA3)–(rSm-p80–R848))
Control protein
vaccine (R848)
Experimental protein
vaccine (rSm-p80–R848)
0 10012.69 1001.52 1002.80 1008.20
2 1007.62 1000.91 1000.87 4009.76
4 1000.00 1002.31 1009.79 3200246.15
6 1004.80 3200285.71 1000.76 12 800696.23
8 1001.48 25 6003131.92 1001.56 25 6001629.09
10 1003.60 51 2004536.71 1002.78 51 2003324.68
12 1005.07 51 2002426.54 1008.11 51 2004633.48
Table 8
End-point titers of anti-Sm-p80 IgM in the sera of C57BL/6 mice following immunization either with prime–boost regimen ((Sm-p80–pcDNA3)–(rSm-p80–R848)) or only
with the recombinant protein (rSm-p80–R848)
Week Control prime–boost
(pcDNA–R848)
Experimental prime–boost
((Sm-p80–pcDNA3)–(rSm-p80–R848))
Control protein
vaccine (R848)
Experimental protein
vaccine (rSm-p80–R848)
0 1000.69 1004.07 1002.86 1000.67
2 1008.09 1000.77 1009.63 2004.30
4 1007.38 1001.65 1002.59 40017.61
6 1008.39 16008.70 1002.21 6400479
8 1006.00 320082.47 1001.28 6400172
10 1006.67 12 800163 10012.26 12 800136
12 1009.74 6400795.27 10016.18 6400533
Table 9
End-point titers of anti-Sm-p80 IgA in the sera of C57BL/6mice following immunization eitherwith prime–boost regimen ((Sm-p80–pcDNA3)–(rSm-p80–R848)) or onlywith
the recombinant protein (rSm-p80–R848)
Week Control prime–boost
(pcDNA–R848)
Experimental prime–boost
((Sm-p80–pcDNA3)–(rSm-p80–R848))
Control protein
vaccine (R848)
Experimental protein
vaccine (rSm-p80–R848)
0 10011.45 1006.21 1005.15 10018.84
2 1004.72 1002.10 1005.11 8009.70
4 1003.23 10014.29 1009.24 3200120.43
6 1005.69 640034.97 1000.91 12 800940.11
8 1004.05 12 800104.92 10017.05 25 6008290.91
10 10020.21 25 6005493.12 10012.40 25 6001055.67
12 1004.05 25 6002203.28 10017.05 25 6005222.4
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Table 10
Levels of cytokine production by splenocytes after 48h stimulation with recombinant Sm-p80 in vitroa
Immunization group IL-2 (pg/ml) IL-4 (pg/ml) IL-10 (pg/ml) IFN-g (pg/ml)
Control prime–boost (pcDNA–R848) 32.320.48 39.230.00 165.8213.72 46.328.03
Experimental prime–boost ((Sm-p80–pcDNA3)–(rSm-p80–R848)) 164.004.85b 41.419.96 88.474.16 144.6421.47b
Control protein vaccine (R848) 32.102.55 40.8810.64 123.684.23 48.098.61
Experimental protein vaccine (rSm-p80–R848) 1691.8942.01b 39.747.95 204.45105.32 408.7435.61b
IL, interleukin; IFN, interferon.
a The values in the table represent mean SD.
b p  0.05 vs. corresponding control group stimulated by recombinant Sm-p80 using the independent sample t-test.
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vaccinated group of animals, reaching a peak of 1:12 800 at 10
weeks post-immunization, gradually declining thereafter
(Table 8). The titer of IgA antibody was also monitored in the
present study and a high level of IgA antibody could be detected in
both of the vaccination regimens (Table 9). The end-point titer for
IgA antibody stood at 1:25 600 at 12 weeks post-immunization.[(Figure_1)TD$FIG]
Figure 1. Relative cytokine mRNA expression levels by splenocytes after 48 h
stimulation with recombinant Sm-p80 in vitro. The relative cytokine mRNA
expressionwas calculated by comparing the differences in themessage levels of the
control group with the respective experimental group after standardization using
glyceraldehyde 3-phosphate dehydrogenase (GAPDH); (A) ‘DNA prime–protein
boost’ group; (B) ‘recombinant protein–R848’ group..3.4. Cytokine production
High levels of IL-2 and IFN-g were detected in the supernatant
of cultured splenocytes 48 h after culture, as detected by ELISA in
both the ‘DNA prime–protein boost’ and ‘recombinant protein–
R848’ vaccinated group as compared with their respective control
groups (Table 10). However no signiﬁcant increase in the level of
IL-4 or IL-10 was observed for either vaccination regimen group.
3.5. mRNA expression proﬁles of cytokines as detected by RT-PCR
Using RT-PCR, the mRNA expression proﬁles of a number of
cytokines (IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8 (= MIP-
2), IL-9, IL-10, IL-11, IL-12a, IL-12b, IL-13, IL-14, IL-15, IL-16, IL-17,
IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, TNF-a, IFN-g, TGF-b1, TGF-
b2) and GAPDHwere determined and the results thus obtained are
shown in Figure 1. Relative gene expression was calibrated to the
expression of the GAPDH gene and reported as fold relative
difference levels in the normalization of normal control samples. In
the ‘DNA prime–protein boost’ group (Figure 1A), higher levels of
IL-2, IL-3, IL-12a, IL-15 and IFN-g genes were expressed, while in
the case of the ‘recombinant protein–R848’ group, besides high
level expression of IL-2 and IFN-g genes, several additional
cytokines genes, for example, IL-6 and IL-16, were also up-
regulated (Figure 1B).
4. Discussion
In immunization approaches with the aim of stimulating
protective immune responses with the potential to facilitate the
host in rejecting the initial establishment and subsequent sexual
maturation of the parasite, the choice of immune-enhancer is of
signiﬁcant importance. Although Sm-p80 has been shown to be
exposed at the host–parasite interface of larval and adult parasites
and is naturally immunogenic, this natural immunogenicity of the
molecule does not stimulate the immune responses that could
protect the host from infection.19–23 We have previously demon-
strated that Sm-p80 can protect murine as well as nonhuman
primate animals signiﬁcantly against experimental schistosomia-
sis if presented in such a way that it induces a Th1-skewed
protective immune response.3,8–11,24–26 For example, recently11
using oligodeoxynucleotide (ODN) 10104 (Coley Pharmaceutical
Group, Wellesley, MA, USA) as an adjuvant we could enhance the
immunoprotective efﬁcacy of Sm-p80 leading to a reduction in
worm burden of 70%, a protection level previously reported only
with irradiated cercarial vaccine.27–29
In our continual efforts to improve the efﬁcacy of Sm-p80 by
enhancing the Th1-type protective immune response, we studied
the adjuvant effect of a TLR 7/8 agonist imidazoquinolinamine
compound – resiquimod. Resiquimod has demonstrated potency
as an inducer of the Th1 response enhancer cytokines both in vitro
and in vivo30 and also stimulates dendritic cells to secrete
cytokines, up-regulate co-stimulatory molecule expression, and
enhance antigen presentation to T cells. Additionally, R848 has
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models.31
In the present study we designed two experiments, expecting
Sm-p80 delivered in combinations with R848 either in a ‘DNA
prime–protein boost’ approach or ‘recombinant Sm-p80 protein–
R848’ approach to augment its protective efﬁcacy. As expected,
resiquimod did indeed enhance the antigen-speciﬁc total IgG
responses (1:204 800 titer) and also shifted the response towards
the Th1-type, as determined by higher levels of production of
IgG2a following immunizationwith the ‘DNAprime–protein boost’
vaccination strategy. However the elevation of IgG2a did not lead
to higher protection levels in terms of worm reduction and
reduction in egg production, as previously was observed using
ODN 10104 as an adjuvant.11 Besides this, the proliferating
splenocytes secreted signiﬁcantly higher levels of IL-2 and IFN-g in
the culture supernatants. Traditionally it has been reported that
IFN-g plays a signiﬁcant role in vaccine-mediated protection
against schistosome challenge infection in animal model stud-
ies.8,9,11,24,26,32–35 The up-regulation in expression of IL-12 may be
the reason for a very high titer of IgG2a antibodies. Previously it has
been reported that IL-12 induces a switch in immunoglobulin
isotypes by acting on B cells both directly and indirectly via T-cell-
derived IFN-g, resulting in enhanced production of IgG2a
antibodies and inhibition of IgE synthesis.36 Additionally, in the
present vaccination regimen in mice, as well as the known Th1
response enhancing cytokines, for example IL-2, IFN-g and IL-12a,
up-regulation of IL-3, IL-6, IL-15 and IL-16 was also observed. IL-5
which has structural similarity to IL-2 is involved in the induction
and proliferation of natural killer cells and its regulation has
previously been implicated in enhancing resistance to microbes.37
Up-regulation of IL-16 in the present study is very interesting,
since IL-16 is a multi-functional cytokine that uses CD4 as a
receptor to signal diverse biological activities by target cells,
including T-lymphocytes, monocytes, and eosinophils.38
In conclusion the present study clearly demonstrates that Sm-
p80 consistently maintained its protective nature and that
resiquimod as an immunopotentiating agent slightly boosted
the protective effect of Sm-p80 both in ‘DNA prime–protein boost’
and ‘recombinant protein’ immunization approaches in a murine
animal model.
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